True Experimental Insights: Designing in-vivo care model via anthocyanins' neuroprotective therapeutic potential | [Rawal Medical Journal • 2025]

Author(s):

1. Pashmina Shaikh: Department of Anatomy, LUMHS Jamshoro, Pakistan

2. Umbreen Bano: Department of Anatomy, LUMHS Jamshoro, Pakistan

3. Muryyum Dilshad: Department of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan

4. Sehar Khowaja: Department of Anatomy, Indus Medical College Tando Mohammad Khan, Sindh, Pakistan

5. Asim Mehmood: Department of Anatomy. Suleman Roshan Medical College Tando Adam, Pakistan

6. Sameena Gul Memon: Department of Anatomy, Bilawal Medical College LUMHS Jamshoro, Pakistan

Abstract:

Objective: To design an in vivo care model via anthocyanins' neuro-protective therapeutic potential. Methodology: In this vivo experiment, 20 healthy male eight weeks old rats were selected, and five groups were formed. Group I was the physiological/noninduced rats, where four other groups (n=16) of various sizes were administered with intraperitoneal injections of propionic acid (250 mg/kg/day for 5 days). Group II (induced with propionic acid PPA), Groups III, IV, and V used anthocyanin at the concentrations of 100 mg/kg, 200 mg/kg, and 400 mg/kg, respectively a regular diet for a total of 4 weeks. ELISA detected neurotrophins levels with Statistical analysis of ANOVA (Post hoc Turkey test). Results: The levels of brain-derived neurotrophic factor (BDNF).were observed in the Anthocyanin-trea-ted groups (III, IV, and V) as compared with the group (II), inferring that Anthocyanin therapy can heal aut-ism like symptoms. The levels of measured BDNF (ng/ ml) were as follows: Group I (12.1 ± 0.5), II (4.1 ±0.5), III (9.1 ±0.5), IV (7.5 ±0.5), and V (9.7 ±0.5). To be specific, BDNF levels in Groups III, IV, and V were higher than in Group II (PPA-induced) (p<0.05). Conclusion: Anthocyanin was found to interact with PPA-induced Autism Mouse models proportional to the recovery in serum BNDF levels.

Page(s): 759-761

DOI: DOI not available

Published: Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Keywords:

Neurodegeneration , anthocyanin , autism models

References:

[1] Saure E,Castrén M,Mikkola K,Salmi J .2023 .Intellectual disabilities moderate sex/gender differences in autism spectrum disorder: a systematic review and meta-analysis. J Intellect Disabil Res, 67 : 1-34.

[2] Wang L,Wang B,Wu C,Wang J,Sun M.,Autism Spectrum Disorder: Neurodevelopmental Risk Factors,Therapy Precision .2023 .. Int J Mol Sci, 24 : 1819-23.

[3] Zaa CA,Marcelo ÁJ,Medina-Franco A Z,Velasco-Velázquez JL,MA JL .2023 .. Anthocyanins: Molecular Aspects on Their Neuroprotective Activity. Biomolecules, 13 : 1598-1602.

[4] Panchal SK .2022 .Potential Benefits of Anthocyanins in Chronic Disorders of the Central Nervous System. Molecules, 28 : 80-4.

[5] Bhat IUH,Bhat R.,Anthocyanin A Bioactive,Compound A Bioactive,Products. Biology A Bioactive .2021 .Imparting Cardiovascular and Neuroprotective Benefits: Scope for Exploring Fresh Produce, Their Wastes,. , 10 : 586-9.

[6] Rahvar M,Owji AA,Mashayekhi FJ .2018 .Effect of anthocyanin on the brain-derived neurotrophic factor gene expression in the rat brain. Bratisl Lek Listy, 119 : 28-31.

[7] Pravikova PD,Arssan MA,Zalivina EA,Kondaurova EM,Kulikova EA,Belokopytova II .2024 .Dopamine receptors and key elements of the neurotrophins (BDNF, CDNF) expression patterns during critical periods of ontogenesis in the brain structures of mice with autism-like behavior (BTBR) or its absence (С57BL/6 J). Vavilovskii Zhurnal Genet Selektsii, 28 : 407-15.

[8] Han YMY,Yau SY,Chan MMY,Wong CK,Chan AS .2022 .Altered Cytokine and BDNF Levels in Individuals with Autism Spectrum Disorders. Brain Sci, 12 : 460-5.

[9] Pan Z,Cui M,Dai G,Yuan T,Li Y,Ji T,Pan Y.,Protective Y. .2018 .Effect of Anthocyanin on Neurovascular Unit in Cerebral Ischemia/Reperfusion Injury in Rats. Front Neurosci, 12 : 947-9.

[10] Banji OJF,Banji D,Makeen HA,Alqahtani SS,Alshahrani S .2022 .The Role of Anthocyanins as Neuroprotectants. Curr Neuropharmacol, 20 : 2156-74.

[11] Amidfar M,Garcez ML,Askari G,Bagherniya M,Khorvash F,Golpour-Hamedani S .2024 .Role of BDNF Signaling in the Neuroprotective and Memory-enhancing Effects of Flavonoids in Alzheimer's Disease. CNS Neurol Disord Drug Targets, 23 : 984-95.

[12] Mirza MA,Mahmood S,Hilles AR,Ali A,Khan MZ,Zaidi SAA,Review. Pharmaceuticals SAA .2023 .Anthocyanin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications -. , 16 : 1631-4.

[13] Bazzari AH,Bazzari FH .2022 .BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders. Int J Mol Sci, 23 : 8417-9.

[14] Bellavite P. Neuroprotective .2023 .Potentials of Flavonoids: Experimental Studies and Mechanisms of Action. , 12 : 280-4.

[15] Alanazi AS .2013 .The role of nutraceuticals in the management of autism. Saudi Pharm J, 21 : 233-43.

[16] Curpan AS,Luca AC,Ciobica A .2021 .Potential Novel Therapies for Neurodevelopmental Diseases Targeting Oxidative Stress. Oxid Med Cell Longev, : 6640206.

[17] Chiang MC,Tsai TY,Wang CJ .2023 .The Potential Benefits of Anthocyanin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms. Int J Mol Sci, 24 : 6328-32.

[18] Majhi S,Kumar S,Singh L S .2023 .A Review on Autism Spectrum Disorder: Pathogenesis, Biomarkers, Pharmacological and NonPharmacological Interventions. CNS Neurol Disord Drug Targets, 22 : 659-77.

Citations

Downloads

Views